Please Wait...

CXCL8/IL8 // C-X-C motif chemokine 8 / Interleukin 8

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

CXCL8 was the first characterized chemokine and was initially named IL-8. CXCL8, expressed by activated Th17 helper cells, attracts and activates neutrophils cells (Walz et al., 1987).

CXCL8 bind two different receptors: CXCR1 and CXCR2. CXCR1 is specific for CXCL8 and CXCR2 binds also CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 and CXCL7. Under physiological conditions, CXCL8 exists as monomers and dimers and both forms bind the receptors but the monomeric forms have a better ability to induce CXCR1 phosphorylation, desensitization and internalization (whereas both forms induce these actions for CXCR2). Dimerization of CXCL8 is then implicated in the regulation of inflammatory response (Nasser et al., 2009).

 

CXCL8-IL8 assay is a solid phase enzyme linked immunoassay which has been validated in the laboratory for measurement in human serum.

 

Nasser, M.W., Raghuwanshi, S.K., Grant, D.J., Jala, V.R., Rajarathnam, K., and Richardson, R.M. (2009). Differential Activation and Regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer. J. Immunol. Baltim. Md 1950 183, 3425–3432.

Walz, A., Peveri, P., Aschauer, H., and Baggiolini, M. (1987). Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes. Biochem. Biophys. Res. Commun. 149, 755–761.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Join Bioclinica in a live #Xtalks webinar 10/31 exploring challenges & benefits of different sourcing models to man… https://t.co/kRYNc1Z3gj
bioclinica (2 hours ago)
Bioclinica contributions toward advancement of #Alzheimer's disease research & therapies showcased in 8 different s… https://t.co/j96UN9568o
bioclinica (8 hours ago)
Bioclinica’s Joby John reflects on the #SCDM2018 Annual Conference & being a part a thriving community of clinical… https://t.co/c70gH5kJo9
bioclinica (Yesterday)
RT @bioclinica: Our own Jeff Heilbraun is in Tokyo nxt wk to lead a discussion at DIA’s Cardiac Safety Workshop in Japan. Jeff will give an…
bioclinica (Yesterday)
RT @Xtalks: Trends in #SitePayments: Insight into How CROs Can Gain a Competitive Edge This webinar will focus on the latest market researc…
bioclinica (Yesterday)
Great connecting w @bioclinica clients Odonate Therapeutics, Eisai, & PCI Biotech, at #ESMO18 #oncology… https://t.co/4wKrLof8e6
bioclinica (Yesterday)

Latest Blogs:

Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner